Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q2 2026 › vs Q1 2026
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2026 vs Q1 2026 (quarter over quarter)
NewAmsterdam Pharma Co N.V.'s revenue rose $661K (+22%) from $3.0M in Q1 2026 to $3.7M in Q2 2026.
NewAmsterdam Pharma Co N.V., Q2 2026: revenue $3.7M (-81% year over year), net loss $64.1M, operating cash flow −$39.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $661K | +22% |
| Other income, net | $729K | $10.0M | −$9.2M | -93% |
| Net loss | $64.1M | $48.4M | $15.7M | +32% |
| Costs & expenses | $68.6M | $61.5M | $7.1M | +12% |
| Operating costs | $68.6M | $61.5M | $7.1M | +12% |
| Research & development | $41.7M | $38.0M | $3.7M | +10% |
| SG&A | $26.9M | $23.5M | $3.4M | +15% |
| Operating cash sources | $64.1M | $48.4M | $15.7M | +32% |
| Depreciation & amortization | $59K | $62K | −$3K | -5% |
| Share-based compensation | $18.4M | $18.0M | $379K | +2% |
| Working capital & other | $6.5M | −$227K | $6.7M | — |
| Cash used in operations | $39.2M | $30.6M | $8.6M | +28% |
| Net loss absorbed | $64.1M | $48.4M | $15.7M | +32% |
Questions
How much did NewAmsterdam Pharma Co N.V.'s revenue grow quarter over quarter in Q2 2026?
NewAmsterdam Pharma Co N.V.'s revenue rose $661K (+22%) from $3.0M in Q1 2026 to $3.7M in Q2 2026.